ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company focuses on controlled substances, oncology products, hormones and steroids, and injectables.

55/100 AI Score MCap $1.77B Vol 216.1K

Company Overview

CEONikhil Lalwani
Employees897
HeadquartersBaudette, MN, US
IPO Year2000

ANI Pharmaceuticals offers a diversified portfolio of branded and generic pharmaceuticals, specializing in complex formulations and niche markets. With a focus on controlled substances, oncology, and hormones, ANI presents a compelling investment in the specialty generics space, targeting sustainable growth and profitability.

Investment Thesis

ANI Pharmaceuticals presents a compelling investment opportunity due to its diversified product portfolio, strategic focus on niche markets, and strong manufacturing capabilities. With a current P/E ratio of 43.13 and a gross margin of 58.4%, ANI demonstrates solid profitability and financial health. Key value drivers include the company's expertise in manufacturing complex formulations, its established distribution network, and its ability to identify and capitalize on market opportunities in the specialty generic and branded pharmaceutical sectors. Upcoming catalysts include potential new product launches and strategic acquisitions that could expand ANI's product portfolio and market reach. Investors should consider ANI for its potential to deliver sustainable growth and long-term value in the biopharmaceutical industry.

Key Highlights

  • Market capitalization of $1.84 billion reflects investor confidence in ANI's growth potential.
  • Gross margin of 58.4% indicates efficient operations and strong pricing power.
  • Profit margin of 4.6% demonstrates profitability in a competitive market.
  • Beta of 0.50 suggests lower volatility compared to the overall market.
  • Focus on controlled substances, oncology products, and hormones provides access to specialized and high-demand markets.

Competitors

Strengths

  • Diversified product portfolio
  • Specialized manufacturing capabilities
  • Established distribution network
  • Focus on niche markets

Weaknesses

  • Relatively small market capitalization
  • Dependence on a limited number of key products
  • Exposure to generic competition
  • Limited international presence

Catalysts

  • Upcoming: Potential new product launches in the generic and branded pharmaceutical markets.
  • Ongoing: Expansion of contract manufacturing services to other pharmaceutical companies.
  • Ongoing: Strategic acquisitions of complementary businesses or product portfolios.

Risks

  • Potential: Increasing competition from generic manufacturers could erode market share and profitability.
  • Potential: Pricing pressures from payers could reduce revenue and margins.
  • Ongoing: Regulatory changes could increase compliance costs and delay product approvals.
  • Potential: Product liability claims could result in significant financial losses.

Growth Opportunities

  • New Product Launches: ANI has opportunities to launch new generic and branded products, expanding its portfolio and revenue streams. The company can leverage its manufacturing capabilities and regulatory expertise to bring new drugs to market, targeting unmet medical needs and underserved patient populations. The market for generic drugs is expected to reach $455 billion by 2027, providing a significant opportunity for ANI to capture market share.
  • Strategic Acquisitions: ANI can pursue strategic acquisitions of other pharmaceutical companies or product portfolios to expand its market presence and diversify its product offerings. Acquisitions can provide access to new technologies, therapeutic areas, and distribution channels, accelerating ANI's growth and enhancing its competitive position. The company can target companies with complementary product lines or specialized expertise, creating synergies and driving value creation.
  • Contract Manufacturing: ANI can expand its contract manufacturing business, providing manufacturing services to other pharmaceutical companies. The company's expertise in complex formulations and manufacturing processes makes it an attractive partner for companies seeking to outsource their manufacturing operations. The contract manufacturing market is expected to grow to $137 billion by 2028, providing a significant opportunity for ANI to generate additional revenue and profitability.
  • International Expansion: ANI can expand its operations into new international markets, leveraging its product portfolio and manufacturing capabilities to serve patients in other countries. International expansion can provide access to new growth opportunities and diversify ANI's revenue streams. The company can target markets with growing healthcare spending and unmet medical needs, such as emerging economies in Asia and Latin America.
  • Focus on Biosimilars: ANI can invest in the development and manufacturing of biosimilars, which are generic versions of biologic drugs. Biosimilars offer a significant cost advantage over branded biologics, making them an attractive option for patients and payers. The biosimilars market is expected to reach $100 billion by 2029, providing a significant opportunity for ANI to capture market share and drive growth.

Opportunities

  • New product launches
  • Strategic acquisitions
  • Contract manufacturing
  • International expansion

Threats

  • Increasing competition from generic manufacturers
  • Pricing pressures from payers
  • Regulatory changes
  • Product liability claims

Competitive Advantages

  • Specialized Manufacturing Capabilities: Expertise in manufacturing complex formulations and potent products.
  • Established Distribution Network: Strong relationships with retail pharmacy chains, wholesalers, and distributors.
  • Regulatory Expertise: Deep understanding of regulatory requirements for pharmaceutical products.
  • Diversified Product Portfolio: Broad range of generic and branded pharmaceuticals.

About

ANI Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing, and marketing a diverse range of pharmaceutical products. Founded in 2001 and headquartered in Baudette, Minnesota, ANI has established a strong presence in the specialty generic and branded pharmaceutical markets. The company's portfolio includes oral solid dose products, semi-solids, liquids, topicals, and injectables, with a particular emphasis on controlled substances, oncology products, hormones, and steroids. ANI markets its products through a network of retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations across the United States and Canada. In addition to its own product line, ANI provides contract development and manufacturing services to other pharmaceutical companies, leveraging its expertise in complex formulations and manufacturing processes. ANI's commitment to quality, innovation, and strategic partnerships has positioned it as a key player in the pharmaceutical industry, driving growth and delivering value to its stakeholders. The company's focus on niche markets and specialized products allows it to maintain a competitive edge and capitalize on unmet medical needs.

What They Do

  • Develops branded and generic prescription pharmaceuticals.
  • Manufactures oral solid dose products.
  • Produces semi-solids, liquids, and topicals.
  • Specializes in potent products.
  • Offers contract development and manufacturing services.
  • Focuses on controlled substances, oncology products, hormones, and steroids.
  • Markets products through retail pharmacy chains, wholesalers, and distributors.

Business Model

  • Develops and manufactures generic and branded pharmaceuticals.
  • Sells products through various distribution channels, including retail pharmacies and wholesalers.
  • Provides contract manufacturing services to other pharmaceutical companies.
  • Focuses on niche markets and specialized products to maintain a competitive edge.

Industry Context

ANI Pharmaceuticals operates within the specialty generic and branded pharmaceutical industry, a sector characterized by increasing demand for affordable medications and innovative treatments. The industry is driven by factors such as an aging population, rising healthcare costs, and the expiration of patents on blockbuster drugs. ANI competes with other generic and branded pharmaceutical companies, focusing on niche markets and specialized products to differentiate itself. The market is expected to continue growing, driven by increasing healthcare spending and the need for cost-effective treatment options. ANI's focus on complex formulations and manufacturing capabilities positions it well to capitalize on these trends.

Key Customers

  • Retail pharmacy chains
  • Wholesalers
  • Distributors
  • Mail order pharmacies
  • Group purchasing organizations
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $228M $26M $0.00
Q2 2025 $211M $8M $0.00
Q1 2025 $197M $16M $0.00
Q4 2024 $191M -$11M $0.00

Source: Company filings

Chart & Info

Price Chart

ANI Pharmaceuticals, Inc. (ANIP) stock price: $78.90 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential for growth.
  • •Community sentiment has shifted positively, with increased discussions around ANI's recent product launches and their impact on revenue.
  • •Analysts are optimistic about ANI's expansion into new therapeutic areas, which could diversify their portfolio and reduce risk.
  • •The company's recent partnerships have generated buzz, suggesting that ANI is positioning itself strategically within the pharmaceutical landscape.

Why Bear

  • •Concerns remain regarding regulatory challenges that could delay product approvals, creating uncertainty around timelines.
  • •Social sentiment has shown skepticism about the sustainability of recent sales growth, with some investors questioning long-term viability.
  • •Recent earnings reports have raised eyebrows, as some investors feel that revenue projections may be overly ambitious given market conditions.
  • •Market perception is mixed, with some analysts highlighting potential competition that could impact ANI's market share and profitability.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for ANIP including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss ANI Pharmaceuticals, Inc. (ANIP) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for ANIP.

Make a Prediction

Set your price target for ANI Pharmaceuticals, Inc. (ANIP), choose a timeframe, and track your prediction accuracy.

Current price: $78.90

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANIP.

Price Targets

Wall Street price target analysis for ANIP.

Insider Flow (30d)

Cook Meredith
Insider
1 month ago
SOLD
74,374 shares
$6.3M
Davis Krista
Insider
2 months ago
SOLD
58,564 shares
$4.8M
Cook Meredith
Insider
2 months ago
SOLD
74,874 shares
$6.2M
TANNENBAUM RENEE P
Insider
2 months ago
SOLD
25,157 shares
$2.0M

MoonshotScore

54.5/100

Score Factors

  • Revenue Growth 6/100

    Revenue increased 26.2% YoY, reflecting moderate but steady business growth.

  • Gross Margin 10/100

    Gross margin of 60.8% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 6/100

    Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates ANIP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does ANI Pharmaceuticals, Inc. do?

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets a range of branded and generic prescription pharmaceuticals. The company focuses on producing complex formulations, including controlled substances, oncology products, hormones, and steroids. ANI sells its products through retail pharmacy chains, wholesalers, distributors, and mail-order pharmacies. Additionally, ANI provides contract development and manufacturing services to other pharmaceutical companies, leveraging its expertise in specialized manufacturing processes.

Is ANIP stock a good buy?

ANIP stock presents a mixed investment profile. The company's focus on niche markets and specialized products, coupled with a gross margin of 58.4%, suggests potential for profitability. However, the P/E ratio of 43.13 indicates a relatively high valuation. Investors should consider ANI's growth opportunities, such as new product launches and strategic acquisitions, as well as potential risks, such as increasing competition and pricing pressures. A thorough analysis of ANI's financial performance and industry dynamics is essential before making an investment decision.

What are the main risks for ANIP?

ANI Pharmaceuticals faces several key risks, including increasing competition from generic manufacturers, which could erode market share and profitability. Pricing pressures from payers, such as insurance companies and government healthcare programs, could also reduce revenue and margins. Regulatory changes, such as new drug approval requirements or manufacturing standards, could increase compliance costs and delay product launches. Additionally, product liability claims pose a risk to ANI's financial stability and reputation.

Is ANIP a good stock to buy?

Whether ANIP is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the ANIP MoonshotScore?

The MoonshotScore for ANIP is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is ANIP data updated?

ANIP stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ANIP is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for ANIP?

Growth catalysts for ANI Pharmaceuticals, Inc. (ANIP) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes ANI Pharmaceuticals, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are ANIP's main competitors?

ANI Pharmaceuticals, Inc. (ANIP) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ANIP has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about ANIP?

Wall Street analyst coverage for ANIP includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is ANIP's market cap?

Market capitalization (market cap) for ANIP is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ANIP's current market cap alongside enterprise value and other valuation metrics.

How has ANIP stock performed recently?

ANIP's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ANIP's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in ANIP?

Key risk categories for ANIP include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ANIP's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling ANIP?

Insider trading activity for ANIP tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is ANIP a good stock for beginners?

ANI Pharmaceuticals, Inc. (ANIP) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is ANIP for first-time investors?

Every stock carries risk, including ANI Pharmaceuticals, Inc. (ANIP). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ANIP.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on the most recent available information. Stock data pending update.
Data Sources
profilefundamentalsexistingCopy